Welcome to our dedicated page for Lantern Pharma SEC filings (Ticker: LTRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lantern Pharma’s disclosures weave together AI algorithms, biomarker data and early-stage oncology trial updates—material that can overwhelm even seasoned biotech investors. If you’ve asked, “How do I read the Lantern Pharma quarterly earnings report 10-Q filing?” or searched for “Lantern Pharma SEC filings explained simply,” you’re in the right place.
Stock Titan delivers real-time access to every document the company submits to EDGAR and layers it with AI-powered summaries that translate technical jargon into plain English. Within seconds you can:
- Spot Lantern Pharma insider trading Form 4 transactions and receive Lantern Pharma Form 4 insider transactions real-time alerts
- Compare R&D spend and cash runway using our Lantern Pharma earnings report filing analysis
- Review Lantern Pharma 8-K material events explained—from IND acceptances to strategic partnerships
- Dive into a Lantern Pharma annual report 10-K simplified to trace pipeline progress and biomarker strategy
- Examine the latest Lantern Pharma proxy statement executive compensation to see how pay aligns with clinical milestones
Our expert engine highlights why an AI-first biotech discloses certain risk factors, flags coming trial catalysts hidden deep in footnotes, and connects insider sentiment to upcoming readouts. Whether you’re monitoring Lantern Pharma executive stock transactions Form 4 before pivotal data releases or simply understanding Lantern Pharma SEC documents with AI, Stock Titan saves hours and lets you focus on decisions, not page counts.
Lantern Pharma (LTRN) director Lee T. Schalop was granted a stock option award for 5,000 shares under the companys Amended and Restated 2018 Equity Incentive Plan. The option has an exercise price of $4.46 and was granted with a transaction date of 08/19/2025. The award becomes exercisable in equal monthly increments over a 36-month vesting period commencing 09/19/2025 and expires 08/18/2035. The filing reports 5,000 underlying shares held directly following the grant. The Form 4 was submitted by the reporting person, who is identified as a director of the issuer.
Lantern Pharma Inc. reported in a Current Report on Form 8-K dated August 13, 2025 that it will issue a press release announcing its financial results for the second quarter ended June 30, 2025. The Company furnished the press release as Exhibit 99.1 and included a cover page interactive data file as Exhibit 104.
The filing notes the disclosure is furnished, not filed, and therefore is not subject to Section 18 liability or incorporated by reference into other filings. The document identifies Lantern Pharma as an emerging growth company, indicates it elected not to use the extended transition period for new accounting standards, lists its Nasdaq ticker LTRN, principal executive office in Dallas, Texas, and is signed by CFO David R. Margrave.
Lantern Pharma Inc. (LTRN) reported continuing operating losses as it advances three clinical-stage small-molecule candidates and an ADC program while relying on its RADR® A.I. platform. For the six months ended June 30, 2025, the company recorded a net loss of $8,867,798 versus $10,400,316 a year earlier, and net loss per share of $0.82 versus $0.97. Cash and cash equivalents were $6,061,408 and marketable securities were $9,840,366, giving approximately $15.9 million of combined liquidity and working capital of about $12.3 million.
The company noted a substantial doubt about its ability to continue as a going concern absent additional financing but expects existing resources to fund operations into June 2026. In July 2025 Lantern entered an ATM Sales Agreement to offer up to $15.53 million of common stock and sold 15,185 shares for approximately $80,000 through August 12, 2025. Research and development expense decreased to $6.33 million for the six months ended June 30, 2025 from $8.14 million a year earlier, while general and administrative expense was roughly stable at about $3.09 million. The company continues active clinical programs for LP-300 (Phase 2), LP-184 (Phase 1) and LP-284 (Phase 1) and operates the RADR platform and a Starlight subsidiary for CNS development.
Lantern Pharma Inc. will hold its 2025 virtual Annual Meeting on September 19, 2025 at 11:00 a.m. Eastern. Only holders of record as of July 28, 2025 may vote; 10,784,725 shares of common stock were outstanding on the record date. Stockholders will vote to elect six directors, approve a one-time repricing of certain stock options under the 2018 Equity Incentive Plan, ratify EisnerAmper LLP as auditor, and approve an adjournment if needed.
The Board approved the repricing on July 24, 2025: Eligible options have exercise prices > $10 and total 314,633 options (about 25% of 1,235,331 outstanding options) are eligible. Subject to stockholder approval, those options would be amended to an exercise price of $5.04 (125% of the 10-day VWAP ending July 24) and will only be exercisable at that price if the holder remains a service provider through a vesting satisfaction date 12 months after stockholder approval. The Company will recognize any incremental compensation cost under ASC Topic 718. The Board recommends a vote FOR all proposals.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
